Ensign Peak Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Ensign Peak Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-61,601	Closed	-$33.5K	–	1723
2024 Q2	$33.5K	Sell	61,601 -1,805	-3%	-$1.42K	﹤0.01%	1709
2024 Q1	$64.7K	Hold	63,406	–	–	﹤0.01%	1721
2023 Q4	$36.1K	Hold	63,406	–	–	﹤0.01%	1734
2023 Q3	$65.9K	Hold	63,406	–	–	﹤0.01%	1746
2023 Q2	$89.4K	Hold	63,406	–	–	﹤0.01%	1753
2023 Q1	$101K	Hold	63,406	–	–	﹤0.01%	1755
2022 Q4	$92.6K	Hold	63,406	–	–	﹤0.01%	1767
2022 Q3	$271K	Hold	63,406	–	–	﹤0.01%	1754
2022 Q2	$246K	Buy	63,406 +2,891	+5%	+$8.23K	﹤0.01%	1734
2022 Q1	$288K	Hold	60,515	–	–	﹤0.01%	1769
2021 Q4	$221K	Buy	+60,515	New	+$323K	﹤0.01%	1905

Other funds holding VIRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Ensign Peak Advisors's VIRX Position: Q3 2024 in Review

Ensign Peak Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2024, closing a stake of 61,601 shares — an estimated $33.5K sold.

Ensign Peak Advisors first reported a position in VIRX in Q4 2021 and held it in 11 quarters. The position peaked at $288K in Q1 2022. 38 funds tracked by Wall St. Rank hold VIRX as of Q3 2024.

Ensign Peak Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Ensign Peak Advisors sold 61,601 Viracta Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $33.5K.
Ensign Peak Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2021 and held it in 11 quarters.
Ensign Peak Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $288K in Q1 2022.
38 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Ensign Peak Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.